Global lab footprint Eurofins Central Laboratory operates four fully owned laboratories across the US, Europe, Singapore, and China, presenting a sales opportunity to position their globally harmonized testing capabilities for multinational trials and complex programs requiring cross-region consistency.

Extensive testing portfolio With capabilities spanning safety assessments, biomarker development, molecular testing, flow cytometry, pathology, and vaccine support, there is potential to cross-sell complementary assays and integrate endpoints to streamline sponsor timelines and data deliverables.

Clinical trial focus A strong emphasis on standardization, quality, and expert scientific advisory for all trial phases suggests opportunities to target sponsors seeking partner labs that can de-risk trials and provide globally harmonized data.

Growth through expansions Recent facility expansions and RSV capacity enhancements in collaboration with regional partners indicate a readiness to scale with sponsors expanding to new markets or pursuing respiratory/acute disease programs.

Brand and partnerships Strategic collaborations with Eurofins CDMO Alphora and regional labs, plus a track record of awards, offer a narrative for approaching customers about integrated solutions, co-development opportunities, and trusted, long-term outsourcing relationships.